PTC Therapeutics has discontinued development of ataluren as a potential treatment for people with cystic fibrosis caused by a nonsense mutation. The Cystic Fibrosis Foundation is supporting efforts to pursue treatments for people with CF who have a nonsense, splicing or other rare mutations.
Site Search
Showing 11 - 18 of 18 results
Press Release
|
Jan. 12, 2006
|
6 min read
Press Release
|
Feb. 14, 2006
|
3 min read
News
|
March 3, 2017
|
3 min read
Press Release
|
July 16, 2008
|
5 min read
Press Release
|
Dec. 10, 2014
|
3 min read
Expanded Research Lab to Apply Latest Scientific Advances -- Including Stem Cell Research and Gene Editing -- to Accelerate New Treatments for CF
Press Release
|
Sept. 16, 2016
|
3 min read
Press Release
|
March 19, 2015
|
2 min read
Program Aimed at Advancing Search for Therapies Targeting Most Common Mutation of CF
Press Release
|
April 16, 2015
|
3 min read